CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Pfizer
Incyte Corporation
Amgen
Dren Bio
AstraZeneca
Merck Sharp & Dohme LLC
Novartis
BeOne Medicines
Kelonia Therapeutics, Inc.
AVM Biotechnology Inc
BeOne Medicines
Lyell Immunopharma, Inc.
BeOne Medicines
AstraZeneca
BeOne Medicines
BeOne Medicines
BeOne Medicines
Janssen Research & Development, LLC
Nurix Therapeutics, Inc.
Bristol-Myers Squibb
Verismo Therapeutics
Incyte Corporation
Nurix Therapeutics, Inc.
Merck Sharp & Dohme LLC
Novartis
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Genmab
Janssen Research & Development, LLC
Takeda
Grifols Therapeutics LLC
Janssen Research & Development, LLC
AbbVie
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Genmab
Janssen Cilag S.A.S.
Merck Sharp & Dohme LLC
FBD Biologics Limited
AstraZeneca
TCRx Therapeutics Co.Ltd
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AbbVie
Beijing Biotech
AbbVie
Elixiron Immunotherapeutics (Hong Kong) Ltd.
TScan Therapeutics, Inc.
Regeneron Pharmaceuticals